#1 Clinical Trials Search in Europe

Fluorouracil Sodium

Fluorouracil Sodium, a chemotherapeutic agent, is being studied in clinical trials for its potential in treating various types of cancer. This article explores the use of Fluorouracil Sodium in ongoing clinical trials, focusing on its application in combination therapies for metastatic gastric cancer and metastatic colorectal cancer. We’ll discuss the objectives, eligibility criteria, and potential outcomes of these trials to provide a comprehensive overview of the drug’s current research landscape.

Table of Contents

What is Fluorouracil Sodium?

Fluorouracil Sodium, also known as 5-FU, is a chemotherapeutic drug used in the treatment of various types of cancer. It belongs to a class of medications called antimetabolites, which work by interfering with the growth of cancer cells[1].

Medical Conditions Treated

Fluorouracil Sodium is primarily used to treat several types of cancer, including:

  • Metastatic colorectal cancer: Cancer that has spread from the colon or rectum to other parts of the body[2].
  • Metastatic gastric adenocarcinoma: A type of stomach cancer that has spread to other areas[1].

It’s often used in combination with other drugs to enhance its effectiveness in treating these conditions.

How It Works

Fluorouracil Sodium works by interfering with the growth of cancer cells. It does this by:

  • Blocking the formation of DNA (the genetic material in cells) in cancer cells
  • Preventing cancer cells from dividing and multiplying
  • Ultimately leading to the death of cancer cells

This mechanism helps to slow down or stop the growth of tumors[1].

Administration

Fluorouracil Sodium is typically administered through intravenous (IV) infusion. This means it’s given directly into a vein over a period of time. The specific method of administration may include:

  • Intravenous infusion: The drug is slowly injected into a vein over a set period[1].

The drug is available as a solution for injection or infusion[2].

Dosage

The dosage of Fluorouracil Sodium can vary depending on the specific condition being treated, the patient’s body surface area, and other factors. Based on the clinical trial information:

  • The maximum daily dose can range up to 2400-2800 mg/m² (milligrams per square meter of body surface area)[1][2].
  • The total dose over a treatment course can be as high as 60,000-145,600 mg/m²[1][2].

It’s important to note that dosages are determined by healthcare professionals based on individual patient factors and should not be adjusted without medical supervision.

Side Effects

Like all chemotherapy drugs, Fluorouracil Sodium can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Mouth sores
  • Decreased appetite
  • Fatigue
  • Skin changes (rash, dryness, or increased sensitivity to sunlight)
  • Low blood cell counts, which can increase the risk of infection and bleeding

It’s crucial to report any side effects to your healthcare provider promptly[1][2].

Precautions

Before receiving Fluorouracil Sodium, patients should be aware of the following precautions:

  • DPD deficiency: Patients with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may be at higher risk for severe side effects[2].
  • Pregnancy and breastfeeding: Fluorouracil Sodium can harm a developing fetus and should not be used during pregnancy. Breastfeeding is also not recommended while receiving this treatment[1].
  • Other medical conditions: Inform your doctor about any other medical conditions, especially liver or kidney problems, as these may affect how your body processes the drug.

Ongoing Research

Fluorouracil Sodium continues to be studied in clinical trials, often in combination with other drugs. Current research includes:

  • Its use in combination with other drugs like nivolumab and FOLFOX for treating metastatic gastric cancer[1].
  • Its role in biomarker-driven treatment regimens for metastatic colorectal cancer[2].

These studies aim to improve treatment outcomes and explore new ways to use Fluorouracil Sodium effectively in cancer therapy.

Aspect Trial 2023-506753-38-00 Trial 2024-518534-81-00
Cancer Type Metastatic gastric cancer Metastatic colorectal cancer
Main Objective Assess objective response rate at 4 months Investigate efficacy and safety over 3 treatment lines
Key Eligibility PD-L1 CPS ≥5, no prior systemic treatment RAS/BRAF wild-type tumors
Fluorouracil Sodium Dose Max daily: 2800 mg/m², Max total: 145600 mg/m² Max daily: 2400 mg/m², Max total: 60000 mg/m²
Treatment Duration Up to 24 months Up to 12 months
Combination Therapy With nivolumab and FOLFOX With cetuximab and other agents

FAQ

  • What is Fluorouracil Sodium? Fluorouracil Sodium is a chemotherapeutic drug used in cancer treatment. It belongs to a class of medications called antimetabolites and works by interfering with the growth of cancer cells.
  • What types of cancer are being studied with Fluorouracil Sodium in these trials? The clinical trials mentioned are studying Fluorouracil Sodium in the treatment of metastatic gastric cancer and metastatic colorectal cancer.
  • How is Fluorouracil Sodium administered in these trials? In these trials, Fluorouracil Sodium is administered as a solution for injection or infusion, typically given intravenously (through a vein).
  • What are the main objectives of these clinical trials? The main objectives include assessing the efficacy and safety of Fluorouracil Sodium when used in combination with other drugs, evaluating response rates, progression-free survival, and overall survival in patients with specific types of cancer.
  • Are there any specific eligibility criteria for participating in these trials? Yes, eligibility criteria include factors such as the type and stage of cancer, previous treatments, overall health status, and specific genetic markers in some cases. Detailed criteria are provided by each trial to ensure patient safety and study validity.

Ongoing Clinical Trials on Fluorouracil Sodium

  • Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • FOLFOX: A combination chemotherapy regimen that includes FOLinic acid, Fluorouracil, and OXaliplatin.
  • PD-L1: Programmed Death-Ligand 1, a protein that plays a role in suppressing the immune system's response to cancer cells.
  • CPS: Combined Positive Score, a method used to measure PD-L1 expression in cancer cells.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Wild-type (WT): Refers to the normal, non-mutated version of a gene.

References

  1. http://clinicaltrials.eu/trial/study-on-exl01-with-nivolumab-and-folfox-for-first-line-treatment-in-patients-with-pd-l1-cps-%e2%89%a55-metastatic-gastric-cancer/
  2. http://clinicaltrials.eu/trial/study-on-cetuximab-based-treatment-for-metastatic-colorectal-cancer-in-patients-with-ras-braf-wild-type-tumors/